AMGN up +0.14% percent right now. $AMGN High is at 163.86 and the Low 162.02 with current volume of 1,088,689.
Recent News posted below.
AMGN Amgen Inc Recent Headline News
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
PR Newswire - 26 mins ago
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.
AZN: 74.20 (+0.99), AMGN: 162.42 (-0.67)
Midday Glance: Biotechnology companies
AP - 2 hrs 35 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)
Amgen Fights To Protect Neupogen's Exclusivity
Tim Harrison - at Seeking Alpha - Tue Nov 11, 11:31AM CST
AMGN: 162.42 (-0.67)
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:50AM CST
NPS Pharma (NPSP) reported a loss of 2 cents per share in the third quarter of 2014, wider than the year-ago loss of 1 cent per share.
AUXL: 32.63 (-0.07), NPSP: 29.41 (+2.50), AMGN: 162.42 (-0.67), BIOD: 1.57 (+0.07)
Early Glance: Biotechnology companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 382.55 (-4.72), YHOO: 49.05 (-0.36), AMZN: 312.01 (+6.90), BIIB: 324.59 (-3.28), VRTX: 117.49 (+0.55), FEYE: 32.85 (+0.46), LNKD: 231.00 (+1.75), EBAY: 54.19 (+0.30), GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), ABBV: 63.85 (+0.06), REGN: 398.36 (+12.39), CELG: 107.85 (-0.16)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.37 (+0.56), AZN: 74.20 (+0.99), AMGN: 162.42 (-0.67), TEVA: 58.19 (+0.15), THRX: 12.93 (-0.51), GSK: 45.96 (+0.80), SNY: 47.14 (+0.95), REGN: 398.36 (+12.39), NVS: 92.77 (+0.14)
Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 87.93 (+0.22), VRX: 130.03 (+2.04), ALXN: 194.92 (-0.88), AMGN: 162.42 (-0.67), MYL: 53.51 (-0.44), ILMN: 187.88 (-0.39), CELG: 107.85 (-0.16)
Final Glance: Biotechnology companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.77% Rise
Comtex SmarTrend(R) - Mon Nov 10, 3:46PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $160.50 to a high of $163.20. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $162.25 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.42 (-0.67)
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.77%
Comtex SmarTrend(R) - Mon Nov 10, 3:45PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $160.50 to a high of $163.20. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $162.25 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.42 (-0.67)
Post Earnings Update: Amgen Has Climbed 8.1% Higher in Past 2 Weeks (AMGN)
Comtex SmarTrend(R) - Mon Nov 10, 12:30PM CST
Two weeks ago on October 27th, 2014 Amgen (NASDAQ:AMGN) reported earnings and analysts, on average, expected earnings of $2.11 on sales of $5.0 billion. The company actually reported EPS of $2.30 on sales of $5.0 billion, beating EPS estimates by $0.19 and beating revenue estimates by $72.4 million. Shares of Amgen have climbed from $148.20 to $160.25, representing a gain of 8.1% since the company reported earnings 14 days ago.
AMGN: 162.42 (-0.67)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (-0.01), IMGN: 10.09 (+0.14), AMGN: 162.42 (-0.67), LLY: 67.85 (-0.50), ONTX: 4.85 (-0.01), BMY: 58.72 (-0.09), GSK: 45.96 (+0.80), OXGN: 1.92 (-0.06), XLRN: 33.72 (+1.46), KPTI: 43.00 (+0.32), NVS: 92.77 (+0.14)
FDA OK with Amgen's BLA for cholesterol-lowering drug
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:02AM CST
AMGN: 162.42 (-0.67)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.29 (-1.66), ABMD: 33.09 (+0.10), JNJ: 108.91 (+0.09), AMGN: 162.42 (-0.67), EXAS: 22.45 (-0.15), ARAY: 7.02 (+0.12), HOLX: 26.61 (+0.06), PBYI: 240.35 (-4.44)
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
PR Newswire - Mon Nov 10, 8:15AM CST
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 162.42 (-0.67)
Ziarco Raises $33.1 Million in Series B Financing
GlobeNewswire - Mon Nov 10, 6:07AM CST
Ziarco Group Ltd, a biopharmaceutical company focusing on inflammatory skin diseases, today announced the completion of a $33.1 million Series B financing round. New Enterprise Associates, Inc. (NEA) and Lundbeckfond Ventures co-led the round with new investor Amgen Ventures joining the existing investors BVF Partners L.P. and Pfizer Venture Investments. Ed Mathers, partner at NEA, has joined Ziarco's board of directors as Chairman. Johan Kordel, senior partner at Lundbeckfond Ventures, has also joined the board.
AMGN: 162.42 (-0.67)
Hess Corporation Tops Best Value Long-Term Bond Ranking
Donald van Deventer - at Seeking Alpha - Sun Nov 09, 8:58AM CST
PSX: 73.64 (-0.86), SCCO: 30.23 (+0.35), SWY: 34.90 (+0.01), HES: 83.81 (unch), UTX: 108.26 (-0.74), RTN: 103.74 (+0.22), WMT: 79.01 (-0.43), TAP: 76.21 (-0.44), AMGN: 162.42 (-0.67), COP: 71.75 (+0.15), SWK: 95.83 (-0.05), DO: 36.64 (-0.83), IBM: 163.30 (-0.19), CVS: 89.76 (+0.57), CAT: 102.53 (+0.32), PPG: 205.26 (-1.01), WAG: 67.50 (-0.28)
Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 324.59 (-3.28), MDT: 68.99 (+0.28), AMGN: 162.42 (-0.67), SYK: 88.68 (+0.24)
Recent News posted below.
AMGN Amgen Inc Recent Headline News
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
PR Newswire - 26 mins ago
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.
AZN: 74.20 (+0.99), AMGN: 162.42 (-0.67)
Midday Glance: Biotechnology companies
AP - 2 hrs 35 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)
Amgen Fights To Protect Neupogen's Exclusivity
Tim Harrison - at Seeking Alpha - Tue Nov 11, 11:31AM CST
AMGN: 162.42 (-0.67)
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:50AM CST
NPS Pharma (NPSP) reported a loss of 2 cents per share in the third quarter of 2014, wider than the year-ago loss of 1 cent per share.
AUXL: 32.63 (-0.07), NPSP: 29.41 (+2.50), AMGN: 162.42 (-0.67), BIOD: 1.57 (+0.07)
Early Glance: Biotechnology companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 382.55 (-4.72), YHOO: 49.05 (-0.36), AMZN: 312.01 (+6.90), BIIB: 324.59 (-3.28), VRTX: 117.49 (+0.55), FEYE: 32.85 (+0.46), LNKD: 231.00 (+1.75), EBAY: 54.19 (+0.30), GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), ABBV: 63.85 (+0.06), REGN: 398.36 (+12.39), CELG: 107.85 (-0.16)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.37 (+0.56), AZN: 74.20 (+0.99), AMGN: 162.42 (-0.67), TEVA: 58.19 (+0.15), THRX: 12.93 (-0.51), GSK: 45.96 (+0.80), SNY: 47.14 (+0.95), REGN: 398.36 (+12.39), NVS: 92.77 (+0.14)
Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 87.93 (+0.22), VRX: 130.03 (+2.04), ALXN: 194.92 (-0.88), AMGN: 162.42 (-0.67), MYL: 53.51 (-0.44), ILMN: 187.88 (-0.39), CELG: 107.85 (-0.16)
Final Glance: Biotechnology companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)
Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.77% Rise
Comtex SmarTrend(R) - Mon Nov 10, 3:46PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $160.50 to a high of $163.20. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $162.25 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.42 (-0.67)
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.77%
Comtex SmarTrend(R) - Mon Nov 10, 3:45PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $160.50 to a high of $163.20. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $162.25 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.42 (-0.67)
Post Earnings Update: Amgen Has Climbed 8.1% Higher in Past 2 Weeks (AMGN)
Comtex SmarTrend(R) - Mon Nov 10, 12:30PM CST
Two weeks ago on October 27th, 2014 Amgen (NASDAQ:AMGN) reported earnings and analysts, on average, expected earnings of $2.11 on sales of $5.0 billion. The company actually reported EPS of $2.30 on sales of $5.0 billion, beating EPS estimates by $0.19 and beating revenue estimates by $72.4 million. Shares of Amgen have climbed from $148.20 to $160.25, representing a gain of 8.1% since the company reported earnings 14 days ago.
AMGN: 162.42 (-0.67)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (-0.01), IMGN: 10.09 (+0.14), AMGN: 162.42 (-0.67), LLY: 67.85 (-0.50), ONTX: 4.85 (-0.01), BMY: 58.72 (-0.09), GSK: 45.96 (+0.80), OXGN: 1.92 (-0.06), XLRN: 33.72 (+1.46), KPTI: 43.00 (+0.32), NVS: 92.77 (+0.14)
FDA OK with Amgen's BLA for cholesterol-lowering drug
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:02AM CST
AMGN: 162.42 (-0.67)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.29 (-1.66), ABMD: 33.09 (+0.10), JNJ: 108.91 (+0.09), AMGN: 162.42 (-0.67), EXAS: 22.45 (-0.15), ARAY: 7.02 (+0.12), HOLX: 26.61 (+0.06), PBYI: 240.35 (-4.44)
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
PR Newswire - Mon Nov 10, 8:15AM CST
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 162.42 (-0.67)
Ziarco Raises $33.1 Million in Series B Financing
GlobeNewswire - Mon Nov 10, 6:07AM CST
Ziarco Group Ltd, a biopharmaceutical company focusing on inflammatory skin diseases, today announced the completion of a $33.1 million Series B financing round. New Enterprise Associates, Inc. (NEA) and Lundbeckfond Ventures co-led the round with new investor Amgen Ventures joining the existing investors BVF Partners L.P. and Pfizer Venture Investments. Ed Mathers, partner at NEA, has joined Ziarco's board of directors as Chairman. Johan Kordel, senior partner at Lundbeckfond Ventures, has also joined the board.
AMGN: 162.42 (-0.67)
Hess Corporation Tops Best Value Long-Term Bond Ranking
Donald van Deventer - at Seeking Alpha - Sun Nov 09, 8:58AM CST
PSX: 73.64 (-0.86), SCCO: 30.23 (+0.35), SWY: 34.90 (+0.01), HES: 83.81 (unch), UTX: 108.26 (-0.74), RTN: 103.74 (+0.22), WMT: 79.01 (-0.43), TAP: 76.21 (-0.44), AMGN: 162.42 (-0.67), COP: 71.75 (+0.15), SWK: 95.83 (-0.05), DO: 36.64 (-0.83), IBM: 163.30 (-0.19), CVS: 89.76 (+0.57), CAT: 102.53 (+0.32), PPG: 205.26 (-1.01), WAG: 67.50 (-0.28)
Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 324.59 (-3.28), MDT: 68.99 (+0.28), AMGN: 162.42 (-0.67), SYK: 88.68 (+0.24)
